StockData
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG) stock

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30160% above fair value
$70.11−11.44 (-14.03%)

Close on Oct 30, 2026Market cap $9.13BP/E –Yield –

Earnings

10x Genomics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$151.00M
-12.7% on a year earlier
EPS, Q2 FY2026
–
$0.28 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of 10x Genomics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$151.00M-12.7%–Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$150.80M-2.6%–Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026after the close$166.00M+0.6%-$0.13Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$149.00M-1.8%-$0.22Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$172.90M+12.9%$0.28Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$154.90M+9.9%-$0.28Release
Q4 FY2024ended Dec 31, 2024Feb 12, 2025after the close$165.00M-10.3%-$0.40Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024after the close$151.70M-1.2%-$0.30Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$153.10M+4.3%-$0.32Release
Q1 FY2024ended Mar 31, 2024Apr 30, 2024after the close$141.00M+5.0%-$0.50Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024after the close$184.00M+17.8%-$0.41Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

10x Genomics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
growthnon-GAAPFY20260% – +4%–NewFeb 12, 2026
growth over full year 2025non-GAAPFY2026+2% – +5%–NewAug 6, 2026
growth over full year 2025FY20260% – +4%–NewMay 7, 2026
revenueFY2026$610.00M – $630.00M$600.00M – $625.00MRaisedAug 6, 2026
revenueGAAPFY2026$600.00M – $625.00M–NewFeb 12, 2026

Guidance vs results

The last range 10x Genomics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q4 FY2025Revenue$154.00M – $158.00M$166.00MAbove range
Q3 FY2025Revenue$140.00M – $144.00M$149.00MAbove range
Q2 FY2025Revenue$138.00M – $142.00M$172.90MAbove range

Guidance history

Every forecast 10x Genomics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026growth over full year 2025FY2026+2% – +5%New
Aug 6, 2026revenueFY2026$610.00M – $630.00MRaised
May 7, 2026growth over full year 2025FY20260% – +4%New
May 7, 2026revenueFY2026$600.00M – $625.00MNew
Feb 12, 2026growthFY20260% – +4%New
Feb 12, 2026revenueFY2026$600.00M – $625.00MNew
Nov 6, 2025revenueQ4 FY2025$154.00M – $158.00MNew
Aug 7, 2025revenueQ3 FY2025$140.00M – $144.00MNew
May 8, 2025revenueQ2 FY2025$138.00M – $142.00MNew
Feb 12, 2025revenueFY2025$610.00M – $630.00MNew
Oct 29, 2024revenueFY2024$595.00M – $605.00MLowered
Aug 8, 2024revenueFY2024$640.00M – $660.00MLowered
Apr 30, 2024revenueFY2024$670.00M – $690.00MReaffirmed
Feb 15, 2024revenueFY2024$670.00M – $690.00MNew
Nov 2, 2023revenueFY2023$610.00M – $625.00MRaised
Aug 3, 2023revenueFY2023$600.00M – $620.00MRaised
May 3, 2023revenueFY2023$590.00M – $610.00MRaised
Feb 15, 2023revenueFY2023$580.00M – $600.00MNew
Nov 2, 2022revenueFY2022$500.00M – $520.00MReaffirmed
Aug 8, 2022revenueFY2022$500.00M – $520.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases 10x Genomics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 10x Genomics Reports Second Quarter 2026 Financial Results
    Results
  2. 10x Genomics Reports First Quarter 2026 Financial Results
    Results
  3. 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
    Results
  4. 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
    Results
  5. 10x Genomics Reports Third Quarter 2025 Financial Results
    Results
  6. 10x Genomics Reports Second Quarter 2025 Financial Results
    Results
  7. 10x Genomics Reports First Quarter 2025 Financial Results
    Results
  8. 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
    Results
  9. 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
    Results
  10. 10x Genomics Reports Third Quarter 2024 Financial Results
    Results
  11. 10x Genomics Announces Preliminary Select Third Quarter 2024 Results
    Results
  12. 10x Genomics Reports Second Quarter 2024 Financial Results
    Results
  13. 10x Genomics Announces Senior Leadership Changes
    Results
  14. 10x Genomics Reports First Quarter 2024 Financial Results
    Results
  15. 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
    Results